A new blood test for dozens of cancers promises earlier answers — but raises big questions
The headlines
Last week’s presentation at the European Society for Medical Oncology in Berlin put a new-generation blood test back in the headlines: Galleri, a so‑called multi‑cancer early detection (MCED) assay developed by Grail, correctly identified a cancer signal and the likely tissue of origin in a large real‑world cohort and — crucially — picked up many tumours at an early, more treatable stage.
The Pathfinder 2 study followed…